BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20507642)

  • 21. Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction.
    Wappenschmidt B; Becker AA; Hauke J; Weber U; Engert S; Köhler J; Kast K; Arnold N; Rhiem K; Hahnen E; Meindl A; Schmutzler RK
    PLoS One; 2012; 7(12):e50800. PubMed ID: 23239986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional characterization of BRCA1 gene variants by mini-gene splicing assay.
    Steffensen AY; Dandanell M; Jønson L; Ejlertsen B; Gerdes AM; Nielsen FC; Hansen Tv
    Eur J Hum Genet; 2014 Dec; 22(12):1362-8. PubMed ID: 24667779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
    Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
    J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analyzing the effects of BRCA1/2 variants on mRNA splicing by minigene assay.
    Dong Z; Wang Y; Zhang J; Zhu F; Liu Z; Kang Y; Lin M; Shi H
    J Hum Genet; 2023 Feb; 68(2):65-71. PubMed ID: 36446827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive prediction of mRNA splicing effects of BRCA1 and BRCA2 variants.
    Mucaki EJ; Ainsworth P; Rogan PK
    Hum Mutat; 2011 Jul; 32(7):735-42. PubMed ID: 21523855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.
    Jarhelle E; Riise Stensland HM; Mæhle L; Van Ghelue M
    Fam Cancer; 2017 Jan; 16(1):1-16. PubMed ID: 27495310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional classification of BRCA2 DNA variants by splicing assays in a large minigene with 9 exons.
    Acedo A; Hernández-Moro C; Curiel-García Á; Díez-Gómez B; Velasco EA
    Hum Mutat; 2015 Feb; 36(2):210-21. PubMed ID: 25382762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
    Machackova E; Foretova L; Lukesova M; Vasickova P; Navratilova M; Coene I; Pavlu H; Kosinova V; Kuklova J; Claes K
    BMC Cancer; 2008 May; 8():140. PubMed ID: 18489799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naturally occurring BRCA2 alternative mRNA splicing events in clinically relevant samples.
    Fackenthal JD; Yoshimatsu T; Zhang B; de Garibay GR; Colombo M; De Vecchi G; Ayoub SC; Lal K; Olopade OI; Vega A; Santamariña M; Blanco A; Wappenschmidt B; Becker A; Houdayer C; Walker LC; López-Perolio I; Thomassen M; Parsons M; Whiley P; Blok MJ; Brandão RD; Tserpelis D; Baralle D; Montalban G; Gutiérrez-Enríquez S; Díez O; Lazaro C; ; Spurdle AB; Radice P; de la Hoya M
    J Med Genet; 2016 Aug; 53(8):548-58. PubMed ID: 27060066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing.
    Whiley PJ; de la Hoya M; Thomassen M; Becker A; Brandão R; Pedersen IS; Montagna M; Menéndez M; Quiles F; Gutiérrez-Enríquez S; De Leeneer K; Tenés A; Montalban G; Tserpelis D; Yoshimatsu T; Tirapo C; Raponi M; Caldes T; Blanco A; Santamariña M; Guidugli L; de Garibay GR; Wong M; Tancredi M; Fachal L; Ding YC; Kruse T; Lattimore V; Kwong A; Chan TL; Colombo M; De Vecchi G; Caligo M; Baralle D; Lázaro C; Couch F; Radice P; Southey MC; Neuhausen S; Houdayer C; Fackenthal J; Hansen TV; Vega A; Diez O; Blok R; Claes K; Wappenschmidt B; Walker L; Spurdle AB; Brown MA;
    Clin Chem; 2014 Feb; 60(2):341-52. PubMed ID: 24212087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Eight Spliceogenic Variants in BRCA2 Exon 16 by Minigene Assays.
    Fraile-Bethencourt E; Valenzuela-Palomo A; Díez-Gómez B; Acedo A; Velasco EA
    Front Genet; 2018; 9():188. PubMed ID: 29881398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RNA-based analysis of BRCA1 and BRCA2 gene alterations.
    Bonatti F; Pepe C; Tancredi M; Lombardi G; Aretini P; Sensi E; Falaschi E; Cipollini G; Bevilacqua G; Caligo MA
    Cancer Genet Cytogenet; 2006 Oct; 170(2):93-101. PubMed ID: 17011978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interpretation of BRCA2 Splicing Variants: A Case Series of Challenging Variant Interpretations and the Importance of Functional RNA Analysis.
    Nix P; Mundt E; Coffee B; Goossen E; Warf BM; Brown K; Bowles K; Roa B
    Fam Cancer; 2022 Jan; 21(1):7-19. PubMed ID: 33469799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In silico, in vitro and case-control analyses as an effective combination for analyzing BRCA1 and BRCA2 unclassified variants in a population-based sample.
    Rodríguez-Balada M; Roig B; Martorell L; Melé M; Salvat M; Vilella E; Borràs J; Gumà J
    Cancer Genet; 2016 Nov; 209(11):487-492. PubMed ID: 27886673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening of
    Montalban G; Bonache S; Moles-Fernández A; Gisbert-Beamud A; Tenés A; Bach V; Carrasco E; López-Fernández A; Stjepanovic N; Balmaña J; Diez O; Gutiérrez-Enríquez S
    J Med Genet; 2019 Feb; 56(2):63-74. PubMed ID: 30472649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bayes analysis provides evidence of pathogenicity for the BRCA1 c.135-1G>T (IVS3-1) and BRCA2 c.7977-1G>C (IVS17-1) variants displaying in vitro splicing results of equivocal clinical significance.
    Spurdle AB; Lakhani SR; Da Silva LM; Balleine RL; ; Goldgar DE
    Hum Mutat; 2010 Feb; 31(2):E1141-5. PubMed ID: 20020529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incorporation of semi-quantitative analysis of splicing alterations for the clinical interpretation of variants in BRCA1 and BRCA2 genes.
    Montalban G; Bonache S; Moles-Fernández A; Gadea N; Tenés A; Torres-Esquius S; Carrasco E; Balmaña J; Diez O; Gutiérrez-Enríquez S
    Hum Mutat; 2019 Dec; 40(12):2296-2317. PubMed ID: 31343793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families.
    Tesoriero AA; Wong EM; Jenkins MA; Hopper JL; Brown MA; Chenevix-Trench G; Spurdle AB; Southey MC;
    Hum Mutat; 2005 Nov; 26(5):495. PubMed ID: 16211554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minigene Splicing Assays Identify 12 Spliceogenic Variants of
    Fraile-Bethencourt E; Valenzuela-Palomo A; Díez-Gómez B; Caloca MJ; Gómez-Barrero S; Velasco EA
    Front Genet; 2019; 10():503. PubMed ID: 31191615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA2 T2722R is a deleterious allele that causes exon skipping.
    Fackenthal JD; Cartegni L; Krainer AR; Olopade OI
    Am J Hum Genet; 2002 Sep; 71(3):625-31. PubMed ID: 12145750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.